BACKGROUND: Two phase 3, multicenter, double-blind trials on HBeAg-positive and HBeAg-negative patients demonstrate that, compared with lamivudine, entecavir is superior in inducing histologic improvement, serum HBV DNA suppression and transaminase normalization. Since intrahepatic HBV DNA and covalently closed circular (ccc) DNA are important for control of viral replication, the efficacy of entecavir vs. lamivudine in achieving suppression of these entities should be studied. METHODS AND PATIENTS: The patients involved in this study were recruited from patients participating in the two phase 3 entecavir trials at our center in Hong Kong. Forty chronic hepatitis B patients (14 HBeAg-positive and 26 anti-HBe-positive) were randomized to rec...
Background: The aim of this study was to determine the efficacyof entecavir-lamivudine sequential th...
Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have fa...
Background: Prolonged use of lamivudine in patients coinfected with HIV and hepatitis B virus (HBV) ...
Entecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) r...
BACKGROUND AND AIMS: Telbivudine has been shown to have a higher rate of reduction of serum hepatiti...
Background/Aims: We investigated the efficacy of entecavir in lamivudine-experienced and -naive pati...
Background & Aims: Entecavir is a novel and selective nucleoside analogue with potent activity again...
The aim of this study was to assess the effect of 48-week entecavir therapy on serum and intrahepati...
PostersThis journal suppl. is Abstract Book of The International Liver Congress™ 2011BACKGROUND AND ...
Background: Entecavir is a potent and selective guanosine analogue with significant activity against...
We aimed to determine the 2-year outcomes of entecavir followed by lamivudine in patients with undet...
This study was undertaken to compare the early antiviral activity and viral kinetic profiles of ente...
BACKGROUND: In a recent study we demonstrated that serum covalently closed circular (ccc) hepatitis ...
BACKGROUND & AIMS: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-n...
BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in ph...
Background: The aim of this study was to determine the efficacyof entecavir-lamivudine sequential th...
Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have fa...
Background: Prolonged use of lamivudine in patients coinfected with HIV and hepatitis B virus (HBV) ...
Entecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) r...
BACKGROUND AND AIMS: Telbivudine has been shown to have a higher rate of reduction of serum hepatiti...
Background/Aims: We investigated the efficacy of entecavir in lamivudine-experienced and -naive pati...
Background & Aims: Entecavir is a novel and selective nucleoside analogue with potent activity again...
The aim of this study was to assess the effect of 48-week entecavir therapy on serum and intrahepati...
PostersThis journal suppl. is Abstract Book of The International Liver Congress™ 2011BACKGROUND AND ...
Background: Entecavir is a potent and selective guanosine analogue with significant activity against...
We aimed to determine the 2-year outcomes of entecavir followed by lamivudine in patients with undet...
This study was undertaken to compare the early antiviral activity and viral kinetic profiles of ente...
BACKGROUND: In a recent study we demonstrated that serum covalently closed circular (ccc) hepatitis ...
BACKGROUND & AIMS: Entecavir demonstrated superior benefit to lamivudine at 48 weeks in nucleoside-n...
BACKGROUND: Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in ph...
Background: The aim of this study was to determine the efficacyof entecavir-lamivudine sequential th...
Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have fa...
Background: Prolonged use of lamivudine in patients coinfected with HIV and hepatitis B virus (HBV) ...